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Abstract
Background: Study aimed to characterise treatment and outcomes for patients with hormone receptor positive
(HR+), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC) within a large regional
cancer centre, as a benchmark for evaluating real-world impact of novel therapies.
Methods: Retrospective longitudinal cohort, using electronic patient records of adult females with a first diagnosis
of HR+/HER2- MBC January 2012–March 2018.
Results: One hundred ninety-six women were identified with HR+/HER2- MBC. Median age was 67 years, 85.2%
were post-menopausal and median time between primary diagnosis and metastasis was 5.4 years. Most (75.1%)
patients received endocrine therapy as first line systemic treatment (1st LoT); use of 1st LoT chemotherapy halved
between 2012 and 2017. Patients receiving 1st LoT chemotherapy were younger and more likely to have visceral
metastasis (p < 0.01). Median OS was 29.5 months and significantly greater for patients with exclusively non-visceral
metastasis (p < 0.01). The adjusted hazard ratio for death of patients with visceral (or CNS) metastasis was 1.91
relative to those with exclusively non-visceral metastasis.
Conclusions: Diverse endocrine therapies predominate as 1st LoT for patients with HR+/HER2- MBC, chemotherapy
being associated with more aggressive disease in younger patients, emphasising the importance of using effective
and tolerable therapies early.
Keywords: Metastatic breast cancer, HR+/HER2-, Chemotherapy, Endocrine therapy, Overall survival
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: c.j.twelves@leeds.ac.uk
†Chris Twelves and Sue Cheeseman contributed equally as first authors.
†Geoff Hall and Tim Perren are senior authors.
1Clinical Cancer Pharmacology and Oncology, Leeds Cancer Centre, St
James’s University Hospital, Level 4, Bexley Wing, Beckett Street, Leeds LS9
7TF, UK
2University of Leeds, Leeds, UK
Full list of author information is available at the end of the article
Twelves et al. BMC Cancer           (2020) 20:53 
https://doi.org/10.1186/s12885-020-6527-y
Background
Breast cancer (BC) is biologically heterogeneous, and
genomic signatures are increasingly recognised [1]. Clin-
ical decisions regarding systemic anticancer treatment
(SACT), however, are usually influenced by expression
of oestrogen/progesterone hormone receptor (HR) and
human epidermal growth factor receptor 2 (HER2) sta-
tus [2] along with patient preference, prior therapy (and
tolerability), comorbidities, and organ function [3].
An estimated 60–75% of patients with MBC have HR+/
HER2- disease [4]. Where rapidly progressing visceral dis-
ease is absent, the UK National Institute for Health and
Care Excellence recommends endocrine therapy as first-
line systemic treatment (1st LoT) for such patients [3],
mirroring international recommendations [5–7].
Until recently, 1st LoT endocrine options comprised
selective estrogen receptor modulators (e.g. tamoxifen),
selective estrogen receptor downregulators (e.g. fulves-
trant) or (in post-menopausal women) third generation
aromatase inhibitors (AI; e.g. anastrazole, letrozole or
exemestane) [3]. Subsequently, guidelines have recom-
mended further endocrine therapy, usually with a differ-
ent class of agent, unless rapid disease progression in a
patient raises concerns regarding endocrine resistance,
or a patient has rapidly progressive visceral disease. The
NCCN recommend continuing endocrine therapy for a
maximum of 3 regimens until progression or unaccept-
able toxicity [7].
The treatment landscape for HR+/HER2- MBC has,
however, changed substantially in recent years with the
advent of targeted therapies combined with endocrine
therapy. Administration of the mTOR inhibitor
everolimus in combination with exemestane results in a
significant gain in progression free survival (PFS); im-
provement in overall survival (OS) did not, however,
achieve statistical significance and the combination is as-
sociated with significant additional toxicity [8]. A more
recent target is cyclin-dependent kinase 4/6 (CDK 4/6);
a number of highly selective CDK 4/6 inhibitors have
been licensed and are becoming widely available [9]. Tri-
als of palbociclib, ribociclib and abemaciclib, in combin-
ation with various endocrine therapies, have shown a
consistent and statistically significant doubling of PFS in
the first line metastatic setting, with a lesser, but clinic-
ally significant, prolongation of OS [10, 11]. Similar ben-
efits are seen in the second line metastatic setting [12–
14]. Importantly, tolerability of CDK 4/6 inhibitors is
generally good, the principle toxicities being asymptom-
atic neutropenia (palbociclib and ribociclib) or diarrhea
(abameciclib). The combination of a CDK 4/6 inhibitor
with first or subsequent lines of endocrine therapy, or
the use of everolimus in combination with exemestane
following progression on a non-steroidal AI, are now
considered standards of care [15–17].
Gaining a fuller understanding of current clinical prac-
tice and patient outcomes is important in understanding
the likely impact of these new therapies. There is, how-
ever, relatively little published information on real-world
treatment patterns of patients with HR+/HER2- MBC
prior to the introduction of CDK 4/6 inhibitors. The aim
of this study was to characterise these patients and
describe outcomes within a large regional cancer centre,
as a benchmark against which the real-world impact of
novel therapies can be evaluated. Study objectives in-
clude scoping the potential for more effective treatment
with an AI combined with a CDK 4/6 inhibitor to re-
place chemotherapy as 1st LoT SACT for patients with
HR+/HER2- MBC, or to delay its use until later in the
disease course.
Methods
Study design
This study was conducted using a retrospective longitu-
dinal cohort design, with secondary use of de-identified,
coded and uncoded hospital electronic patient records
(EPR). Patients with a first diagnosis of HR+/HER2-
MBC made between January 2012 and March 2018 were
identified from a major regional NHS cancer centre.
There was no pre-defined minimum period of follow-up,
which varied according to the date of entry into the
study cohort.
Setting
The Leeds Cancer Centre (LCC) serves a metropolitan
catchment area of over 850,000 people for secondary
care at Leeds Teaching Hospitals NHS Trust (LTHT).
Patient pathway manager (PPM) is an in-house LTHT
hospital EPR in routine clinical use since 2003.
This study was conducted by Real-world Evidence Al-
liance Leeds (REAL) Oncology, a collaboration between
LCC, Leeds Institute for Data Analytics (University of
Leeds) and IQVIA Real World Insights. REAL Oncol-
ogy accesses continually updated patient data stored in
PPM, including patient demographics, cancer diagnoses,
tumour staging and anti-cancer therapy. REAL Oncol-
ogy studies are conducted on-site within LTHT under
the strict legal framework governing access to and use of
personal information in the NHS [18].
Patients and methods
Eligible patients were adult females (≥ 18 years old) with
a first diagnosis of HR+/HER2- MBC made during the
study period and whose treatment for MBC was over-
seen or administered at LTHT. They comprised patients
with a first relapse after a previous diagnosis of early
stage BC, defined as ‘recurrent MBC’, and those with
metastatic disease at their initial diagnosis of BC, defined
as ‘de novo MBC’.
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A two-step process of participant identification was
used. A potential cohort was identified from coded
fields in PPM, defining MBC by the International
Classification of Disease (ICD)-10 code C50, and
American Joint Committee on Cancer (AJCC) stage IV.
Where HR or HER2 receptor status was missing in
coded fields, past treatment with endocrine therapy was
used as a proxy for HR+ status and these patients were
included; treatment with trastuzumab was used as a
proxy for HER2+ status and these patients were ex-
cluded. Uncoded EPR for this potential cohort were
then manually reviewed by a consultant oncologist to
update missing variables in coded fields including con-
firmation of HR+/HER2- status.
Patients treated within a clinical trial (prior to or dur-
ing study period) or receiving CDK 4/6 inhibitors (before
their reimbursement) were excluded.
Data variables
Index date was that of first diagnosis with MBC. Follow-
up was defined as the interval between index date and
the confirmed date of death, the censor date (if lost to
follow-up) or study end in March 2018. Where patients
progressed to MBC following a previous diagnosis of
early stage disease, the metastasis-free interval (MFI)
was defined as the time in months between primary
diagnosis of BC and the first diagnosis of metastatic
disease.
Unless otherwise stated, patient and clinical character-
istics were as recorded in PPM at index date, or the date
closest to (and following) index date. TNM staging was
according to the Union for Cancer Control (UICC)/
AJCC TNM classification (7th edition). Histology was
defined in accordance with ICD-10- morphology codes
and grade. Where menopausal status was not recorded
in coded fields or in the uncoded EPR, patients aged 55
years and over were classified as post-menopausal and
those aged less than 55 were classified as of unknown
menopausal status.
Where receptor status was missing in coded fields,
HR+/HER2- receptor status was derived from uncoded
EPR and was defined as HR positive if the pathology re-
port stated ‘positive’ or either oestrogen or progesterone
receptor status score was at least 3 (out of 8) using
immuno-histochemistry (IHC); HER2 was negative if the
pathology report stated ‘negative’, receptor status score
was 0 or 1 by IHC, or score 2 by IHC but negative by
in-situ hybridisation (ISH).
Start dates and planned end dates of chemotherapy
administered to patients were available in PPM. Some
endocrine treatments were available in PPM but full data
on endocrine therapy was collected from uncoded EPR
to ensure all prescriptions were included. Where end
date of endocrine therapy was missing, and no
subsequent treatment was recorded, patients were con-
sidered to be still receiving endocrine therapy until end
of follow up. Treatment with SACT was reported by
regimen, modality (endocrine therapy, endocrine/tar-
geted therapy [i.e. everolimus plus exemestane], or
chemotherapy) and LoT. First LoT was designated as
first SACT given with palliative intent following index
date. Sequential LoT treatment was defined as a differ-
ent therapy received after the start date of previous
treatment. Endocrine therapy potentially prescribed as
“maintenance” following completion of a chemotherapy
regimen was counted as a subsequent LoT, since dates
of progression were not extracted. Treatment duration
was derived from treatment start and end dates.
Following clinical review, patients were excluded if any
one or more of the following applied: undefinable age or
sex; incomplete staging information; undefinable HR or
HER2 receptor status; incomplete sequence of treatment
records (e.g. where an incident diagnosis was made out-
side the LCC); significant other malignancies present at
index date.
Data analysis
Summary statistics were calculated for categorical and
continuous baseline demographic variables as appropri-
ate, including by sub-cohort of metastatic status (‘de
novo’ or ‘recurrent’ MBC). Continuous variables were
described by the mean, standard deviation, median, and
range. Categorical variables were described by the num-
ber and percentage of patients in each category. Univari-
ate analyses were performed to explore relationships
between variables; differences between categorical vari-
ables were tested using Pearson χ2 test, and differences
between continuous variables tested using parametric
two sample t-tests, where appropriate. Where trend over
time was measured, goodness of fit was reported using
R2. Significance level was p < 0.05 using 2-sided testing.
Where sub-cohorts included 5 or fewer individuals,
actual numbers were masked in line with local data
protection policy to prevent potential identification of
individuals.
OS from index date was summarised using the non-
parametric Kaplan Meier method, with date of death
due to any cause as the end-point. Date of death was
confirmed by monthly reconciliation of PPM with Office
for National Statistics death certifications. Data were
stratified by selected baseline characteristics considered
risk factors for survival; log-rank tests were used to com-
pare survival between subgroups. Median OS was re-
ported with 95% confidence intervals (95% CI).
Following testing assumptions, a Cox proportional
hazards (PH) regression model was constructed to esti-
mate the effect of various prognostic variables on sur-
vival, with person-time follow-up as the underlying
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timescale. Covariates included in the model were re-
stricted to those where the data were at least 65%
complete. A step-down modelling strategy initially in-
cluded all candidate confounders in the base-model,
with parameters not significant at the 0.05 level subse-
quently dropped. Where there was evidence of strong
correlation between covariates retained in the model,
each variable in the pair was dropped separately from
the global model to assess best fit. The most desirable
parsimonious model, i.e. the simplest model with the
least assumptions and variables but with greatest ex-
planatory power, was that with the lowest Akaike infor-
mation criterion, with correction for small sample size.
All analyses were done using SAS v9.4 (SAS, Cary,
NC, USA).
Results
Baseline demographic and clinical characteristics
The study population was drawn from a prevalent popu-
lation of 4246 female patients alive with a diagnosis of
BC between 1st January 2012 and 31st March 2018.
Over this 75-month period, 464 patients were identified
with a new diagnosis of locally advanced BC or MBC,
318 of whom (68.5%) had HR+/HER2- disease. In all,
196 women with MBC were eligible for the analysis; 47
(38.5%) of those excluded had locally advanced BC, 35
(28.7%) had participated in a clinical trial, 26 (21.3%)
had incomplete records and the remainder had another
malignancy at index (Additional file 1).
Patient characteristics for the study cohort are summa-
rized (Table 1). Median age was 67 years and the major-
ity of patients were post-menopausal (n = 167, 85.2%).
Median follow-up time was 34months (range 0.3–77).
Approximately two thirds of patients (n = 124, 63.3%)
had recurrent MBC with a median time between
primary diagnosis and metastasis of 5.4 years (range 0.5–
28); the remainder (n = 72, 36.7%) had de novo MBC.
Metastatic disease at index date was exclusively non-
visceral for 73 patients (37.2%) and exclusively visceral
(including CNS sites) for 31 (15.8%); the remaining 88
patients (44.9%) had metastases at both visceral and
non-visceral sites. Bone was the most commonly re-
corded site of metastasis (n = 133, 67.9%).
Treatment for metastatic disease
Almost all patients (n = 192, 98.0%) received SACT during
the study period; the median number of distinct treat-
ments with SACT following index date was 2 (range 1–9).
At some point, almost all patients received endocrine
therapy (n = 182, 94.8%) whereas 91 (47.4%) received
chemotherapy. Seven patients were omitted from analysis
by LoT because initiation of treatment pre-dated confirm-
ation of metastatic disease. Subsequent analyses are based
on the remaining 185 patients receiving SACT post-
diagnosis of MBC, for whom the distributions of site of
metastasis, and de novo and recurrent MBC were similar
to the overall cohort (Table 1).
Patients with recurrent MBC were more likely to have
visceral metastases (n = 75, 62.5%), than those with de
novo MBC (n = 28, 38.9%; p < 0.01). Although visceral
metastases were more frequent amongst patients under
55 years than in older age groups (75.8% [n = 25] and
Table 1 Selected characteristics of patients with metastatic
HR+/HER2- BC
Characteristic Study cohort
(N, %)
Treated with 1st
LoT SACT (N, %)
All patients 196 185
Age at index date, median (range) 67 years (33–92) 68 years (33–92)
< 55 years 39 (19.9%) 34 (18.4%)
55–74 years 99 (50.5%) 97 (52.4%)
75+ years 58 (29.6%) 54 (29.2%)
Pre/peri-menopausala 25 (12.8%) 20 (10.8%)
Post-menopausal 167 (85.2%) 161 (87.0%)
Morphology (1° tumour)
Infiltrating duct carcinoma, NOSb 117 (59.7%) 109 (58.9%)
Lobular carcinoma, NOS 29 (14.8%) 28 (15.1%)
Carcinoma, NOS 26 (13.3%) 26 (14.1%)
Other 24 (12.2%) 22 (11.9%)
Non-visceral metastasis onlyc 73 (37.2%) 66 (35.7%)
Bone 59 (30.1%) 54 (29.2%)
Lymph nodes 24 (12.2%) 21 (11.4%)
Skin and soft tissue 17 (8.7%) 15 (8.1%)
Non-visceral with visceral metastasisc 88 (44.9%) 86 (46.5%)
Bone 74 (37.8%) 73 (39.5%)
Lymph nodes 44 (22.4%) 42 (22.7%)
Skin and soft tissue 10 (5.1%) 10 (5.4%)
Pulmonary 52 (26.5%) 52 (28.1%)
Liver 40 (20.4%) 39 (21.1%)
Pleura 26 (13.3%) 25 (13.5%)
Peritoneum 10 (5.1%) 9 (4.9%)
CNS 6 (3.1%) 6 (3.2%)
Visceral (incl. CNS) metastasis onlyc 31 (15.8%) 29 (15.7%)
Pulmonary 12 (6.1%) 12 (6.5%)
Liver 16 (8.2%) 14 (7.6%)
Pleura 7 (3.6%) 7 (3.8%)
CNS < 6 < 6
Metastatic status
Recurrent metastatic 124 (63.3%) 111 (61.3%)
De novo metastatic 72 (36.7%) 70 (38.7%)
aThere were < 6 patients for whom menopausal status was not defined
bNOS Not otherwise specified
cPatients may have multiple sites of metastases; categories not mutually
exclusive; < 6 patients had metastasis with an unknown site
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60.8% [n = 90], respectively), this difference was not sta-
tistically significant (p = 0.11).
Endocrine therapy
Endocrine therapy was the modality most frequently
used as 1st LoT (n = 127, 68.6%), with a further 12
(6.5%) receiving endocrine/targeted therapy. Median
treatment duration of 1st LoT endocrine (with/without
targeted) therapy was 382 days (range 13–1708). Patients
treated with 1st LoT endocrine most commonly received
an AI (114 patients, 82.0%); tamoxifen (8.6%) or exemes-
tane/everolimus in combination (8.6%) were used less
frequently (Table 2).
Chemotherapy
Forty-six patients (24.9%) received 1st LoT chemother-
apy and median treatment duration was 129 days (range
24–278). The proportion of patients receiving 1st LoT
chemotherapy appeared to decrease between 2012 and
2017 (33.3 and 15.4%, respectively), although this trend
was not statistically significant (R2 = 0.38, p = 0.19).
No single class of chemotherapy predominated as 1st
LoT; 26 patients (56.5%) received single agent
chemotherapy (paclitaxel, capecitabine or docetaxel); the
remaining 20 received combination chemotherapy
(Table 2). Half those patients on combination therapy
had recurrent MBC and carboplatin with paclitaxel (n =
6) was only used for patients with recurrent MBC who
had been treated with (neo)adjuvant chemotherapy.
Epirubicin and cyclophosphamide (EC; n = 14) was only
used for patients with visceral metastasis, whether with
recurrent MBC following (neo)adjuvant treatment with
endocrine or with de novo MBC.
Factors influencing use of chemotherapy as 1st line SACT
Age and site of metastasis
Patients receiving 1st LoT chemotherapy were younger
(median age 59, range 33–84; p < 0.01), more likely to be
pre/peri-menopausal (n = 9, 45.0%; p = 0.02) and more
likely to have visceral metastasis (n = 41, 89.1%; p < 0.01)
than those receiving endocrine or endocrine/targeted
treatment (Table 3). Very few patients with exclusively
non-visceral metastasis at index date (< 10%) were
treated with 1st LoT chemotherapy.
Of the 115 patients with visceral metastasis, 17
(68.0%) of those aged under 55 years were treated
with chemotherapy compared with fewer than 6.0% of
those aged 75 years and over (p < 0.01) (Table 3). The
66 patients with exclusively non-visceral metastasis
were, however, almost always treated with 1st LoT
endocrine (with/without targeted) therapy, regardless
of their age (Table 3).
Mode of presentation with MBC
Patients with recurrent MBC were somewhat more likely
to be treated with 1st LoT chemotherapy (n = 31, 27.4%)
than those with de novo MBC (n = 15, 20.8%); this dif-
ference in treatment modality was not, however, statisti-
cally significant (p = 0.31).
Influence of prior (neo)adjuvant treatment and MFI
All 124 patients with recurrent metastatic disease had
received (neo)adjuvant endocrine therapy, with or with-
out (neo)adjuvant chemotherapy. Sixteen patients
(12.9%) developed metastatic disease within 24months
of primary diagnosis and 29 patients (23.4%) at least 120
months after that diagnosis; the median MFI was 64.9
months (range 5.6–339.2). This implies that around half
of those developing recurrent MBC will have done so
whilst on (neo)adjuvant endocrine therapy. Those with
MFI longer than average will have been progressively
less likely to have relapsed whilst receiving (neo)adjuvant
endocrine therapy.
The length of MFI was associated with young age at
index date, patients aged under 55 years having the
shortest MFI (p = 0.01); duration of MFI was not, how-
ever, associated with the likelihood of developing visceral
metastasis (p = 0.93). 1st LoT chemotherapy was signifi-
cantly more common than 1st LoT endocrine therapy in
patients with an MFI less than 60months (61.3 and
40.2%, respectively; p = 0.03), indicating increased use of
chemotherapy in those relapsing whilst on (neo)adjuvant
endocrine therapy.
Second LoT and subsequent SACT
Of the 185 patients receiving 1st LoT, 123 (66.5%) re-
ceived subsequent SACT. The mean proportion chan-
ging to further treatment following 1st to 3rd LoT was
Table 2 Treatments received by patients at first line of therapy
following diagnosis of metastatic disease, showing the
percentage of patients in each modality of therapy
Treatment at 1st LoT N % of modality
Endocrine (including targeted) 139 100
Letrozole 56 40.3
Anastrozole 35 25.2
Exemestane 23 16.5
Tamoxifen 12 8.6
Everolimus + exemestane 12 8.6
Other < 6
Chemotherapy 46 100
Paclitaxel 16 34.8
Epirubicin + cyclophosphamide 14 30.4
Capecitabine 7 15.2
Carboplatin + paclitaxel 6 13
Other < 6
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64.1%, falling to 51.8% following 4th to 6th LoT (Fig. 1).
Of those receiving 1st LoT chemotherapy, 39 (84.8%)
had subsequent SACT, compared with 84 (60.4%) of
those receiving 1st LoT endocrine (with/without tar-
geted) therapy (p < 0.01). The extent to which this subse-
quent treatment represents “maintenance” endocrine
therapy without disease progression is, however, not
known.
Following 1st LoT endocrine (with/without targeted)
therapy or chemotherapy, 62 patients did not receive
subsequent SACT; 36 of these patients (58.0%) died dur-
ing or following 1st LoT, the remainder either having
completed or continuing 1st LoT. Following 2nd LoT
SACT, 48 patients did not receive further SACT, 29
(60.4%) having died during or following 2nd LoT. By the
end of the study period, 61.1% treated patients had died,
with the remainder being alive either on or off SACT
(Fig. 1).
The sequence of chemotherapy and endocrine (with/
without targeted) therapy received by patients from 1st
to 3rd LoT was diverse (Fig. 2a). Of the 185 patients
who received 1st LoT, 171 (92.4%) received endocrine
(with/without targeted) therapy and 85 (45.9%) received
chemotherapy at some time during the study period.
When given, 2nd LoT was more often endocrine (with/
without targeted) therapy (n = 96, 77.4%) than
Table 3 Association of age group with site of metastasis and 1st LoT treatment modality for patients treated with 1st LoT SACT
Age group (years) χ2
< 55 (n = 33) 55–74 (n = 95) 75+ (n = 53) total
All (n = 181) Non-visceral only 8 (24.2%) 39 (41.1%) 19 (35.8%) 66 (36.5%) p = 0.223
Visceral 25 (75.8%) 56 (58.9%) 34 (64.2%) 115 (63.5%)
Non-visceral mets only (n = 66) Chemo < 6 < 6 < 6 < 6 p = 0.495a
Endo +/−targ 7 (87.5%) 37 (94.9%) 17 (89.5%) 61 (92.4%)
Visceral mets (incl. brain) (n = 115) Chemo 17 (68.0%) 22 (39.3%) < 6 41 (35.7%) p < 0.001
Endo +/−targ 8 (32.0%) 34 (60.7%) 32 (94.1%) 74 (64.3%)
All (n = 181) Chemo 18 (54.5%) 24 (25.3%) < 6 46 (25.4%) p < 0.001
Endo +/−targ 15 (45.5%) 71 (74.7%) 49 (92.5%) 135 (74.6%)
aFreeman-Halton Fisher exact test statistic
Chemo Chemotherapy, Endo +/−targ Endocrine (with or without targeted) therapy
Fig. 1 Treatment (Tx) outcomes for each distinct LoT (up to 6 LoT shown), including status at end of study. The percentage of patients receiving
subsequent treatment (shown by an arrow between bars) is labelled. The numbers of patients dying before receiving subsequent treatment are
distinguished from those remaining alive without a change of treatment before end of study period
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chemotherapy (n = 28, 22.6%) (Fig. 2a). When given, 3rd
LoT was again more often endocrine (with/without tar-
geted) therapy (n = 49, 65.3%) than chemotherapy (n =
26, 34.7%).
There was substantial diversity in the sequence of
SACT classes and regimens used (Additional file 2). One
line of endocrine therapy with a single agent AI, was the
treatment sequence used most frequently (27.6%, n = 51
patients). The next most common were three successive
lines (n = 19, 10.3%) and two successive lines (n = 17,
9.2%) of endocrine therapy, each without targeted ther-
apy. The fourth most common treatment sequence was
the first to include chemotherapy, (3rd LoT capecitabine
following endocrine therapy; n = 8, 4.3%).
Patients receiving 1st LoT chemotherapy were more
likely than those receiving endocrine (with/without
targeted) therapy to receive subsequent chemotherapy
(26.1 and 11.5%, respectively; p = 0.02: Fig. 2b). Regard-
less of 1st LoT modality, all patients receiving 2nd LoT
chemotherapy either subsequently received further
Fig. 2 Sequence of treatment (Tx) categories given following diagnosis with metastatic disease, showing treatments from 1st LoT (inner ring)
through to a third treatment (outer ring): a all treatment category sequence, b treatment sequence as proportion of 1st LoT category (endocrine
and targeted therapy categories combined) showing proportion of patients dying following treatment at each LoT. Treatment categories beyond
a third treatment are not shown
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treatment or died. In contrast, 18 patients (18.8%) re-
ceiving 2nd LoT endocrine (with/without targeted) ther-
apy remained alive with no further change of treatment
until study end.
Overall survival
Median OS for the study cohort (n = 192) following
diagnosis of metastatic disease was 29.5 months (95% CI:
23.3–34.4). For patients receiving 1st LoT chemotherapy,
median OS was 22.5 months compared to 31.7 months
for those receiving endocrine (with/without targeted)
therapy (p = 0.11) (Fig. 3). Median OS was 31.8 months
in those with de novo MBC compared to 24.2 months in
those with recurrent MBC (p = 0.54); the apparent early
survival benefit in patients with de novo MBC disap-
peared after 36 months (Fig. 3). By contrast, OS was
significantly better for patients with exclusively non-
visceral metastasis than those with visceral metastasis
(median 36.9 months and 22.8 months, respectively; p <
0.01) and this benefit appeared to be regardless of
whether patients had de novo or recurrent MBC
(p = 0.02) and age group (p = 0.03) (Fig. 3). OS was par-
ticularly poor for patients with recurrent MBC who had
visceral metastasis (20.1 months).
Given the observed associations of young age, visceral
metastasis, presentation with recurrent disease and 1st
LoT chemotherapy, a Cox PH analysis was undertaken
to further investigate overall survival. Site of metastasis
and modality of 1st LoT were highly correlated (p <
0.01) and therefore prone to collinearity in the regres-
sion model; modality of 1st LoT was subsequently
dropped from the final model. Presentation with recur-
rent disease was not a significant explanatory variable
for survival and was also dropped, leaving site of metas-
tasis and age. There were 181 patients available for
analysis and 72 patients (39.8%) were censored. Age (p =
0.04) and site of metastasis (p < 0.01) were both signifi-
cant determinants of OS in the combined model; when
adjusted for age, the HR for death for patients with vis-
ceral metastasis was 1.91 (95% CI: 1.27–2.89) relative to
patients with non-visceral metastasis only.
Discussion
This real-world study of patients with HR+/HER2- MBC
between 2012 and early 2018 who had not participated
in a clinical trial is relevant in understanding the poten-
tial future changes in clinical practice at a time when
treatment options are developing rapidly (especially the
introduction of CDK 4/6 inhibitors). In this single-
centre population, almost 70% of patients newly diag-
nosed with advanced or metastatic MBC had HR+/
HER2-. Approximately two thirds of patients had recur-
rent MBC; the remaining third had de novo MBC and
therefore, by definition, had not received previous
SACT.
As expected, and in line with guidelines, almost all pa-
tients (98%) received endocrine therapy at some point
and for three quarters of them, this was the 1st line of
SACT. These patients most frequently received an AI,
commonly letrozole (perhaps reflecting the local use of
anastrazole in the (neo)adjuvant setting). The import-
ance of endocrine therapy in the treatment of HR+/
HER2- MBC is reinforced by the finding that the three
most frequently used sequences of SACT comprise
endocrine therapies alone. The lower proportion of
endocrine-treated patients receiving further SACT (com-
pared with chemotherapy-treated) most likely reflects
the fact that those starting endocrine therapy will con-
tinue with it to disease progression, whereas those
treated with chemotherapy may well switch to endocrine
maintenance prior to progression.
Approximately half (47.5%) of patients received cyto-
toxic chemotherapy, and a quarter received chemother-
apy as 1st LoT. The proportion of patients receiving 1st
LoT chemotherapy decreased over the study period from
greater than 30% to less than 20%; although not
statistically significant, this trend is of interest and
worthy of further study. In a real-world study from the
Netherlands, a quarter of patients with HR+ MBC be-
tween 2007 and 2009 received 1st LoT chemotherapy
[19]; the figure was higher in similar studies from Italy
(42%) [20], US (40%) [21] and Japan (43%) [22], suggest-
ing differences in, and evolution of, practice over time
between countries, despite the consistency of guidelines.
The use of 1st LoT chemotherapy does not contravene
guidelines but is likely to indicate a patient group with
rapidly progressive disease that remained fit enough to
receive it. Indeed, chemotherapy was used as 1st LoT es-
pecially in younger women with visceral disease; a group
potentially more likely to tolerate and benefit from such
treatment. The somewhat greater use of 1st LoT chemo-
therapy in patients with recurrent MBC compared with
de novo MBC may reflect the higher incidence of vis-
ceral disease in the former group. An MFI less than 5
years (usually indicating relapse whilst on (neo)adjuvant
endocrine therapy for patients with recurrent MBC) was
also associated with 1st LoT chemotherapy. Patients
with short MFI in a study from the Netherlands had par-
ticularly poor survival [23], but analyses of treatment
choices were not reported.
Perhaps more surprising, although single agent cape-
citabine and weekly paclitaxel were the most widely used
cytotoxics, almost half 1st LoT chemotherapy was given
in combination, whereas guidelines generally recom-
mend sequential single agent chemotherapy. Patient
numbers were small, but carboplatin/paclitaxel was
given only to those with recurrent disease and prior
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Fig. 3 Five-year OS all causes by (a) modality of 1st LoT (n = 181), b de novo or recurrent metastatic status (n = 196), c site of metastasis (n = 192),
d age group (n = 196), e site of metastasis by age group (n = 192) and f site of metastasis by metastatic status (n = 192)
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chemotherapy treatment and EC chemotherapy was
given only to patients with visceral disease. These as-
sociations suggest that oncologists are “personalising”
their use of chemotherapy as first line SACT. The
heterogeneous treatment patterns resulting from use
of both endocrine therapy (with/without targeted
therapy) and chemotherapy across multiple LoT fur-
ther reinforces the conclusion that treatment of HR+/
HER2- MBC is very much personalised in the real-
world setting. This approach can be expected to
increase with the advent of new treatment options in
the form of CDK4/6 inhibitors [24] and the antici-
pated availability of PI3K inhibitors [25].
After each LoT a significant proportion of patients in
this study did not receive further treatment: some
remained on their current treatment, but others died or
will have been unwilling or unable to receive SACT.
This attrition through subsequent lines of treatment em-
phasizes the importance of utilizing the most effective
and best tolerated SACT sooner rather than later. This
may become more important with the introduction of
CDK4/6 inhibitors, where subsequent delays in the re-
quirement for chemotherapy treatment combined with
lesser impact on OS compared to PFS, may limit the
time for subsequent lines of treatment, be they endo-
crine (with/without chemotherapy) or chemotherapy
[10, 11]. As yet, there is a paucity of trial data on the ef-
ficacy of SACT following 1st LoT endocrine therapy
combined with a CDK4/6 inhibitor. Preliminary real-
world experience suggests that chemotherapy remains
effective and tolerable following a CDK4/6 inhibitor but
there is a need for more data [26].
Median OS in this real-world study cohort was approxi-
mately 30months following the diagnosis of MBC and
worse for those receiving 1st LoT chemotherapy (23
months) than for those receiving endocrine (with or
without targeted) therapy (32months), although this dif-
ference did not reach statistical significance in our study.
In the study from the Netherlands, those initially receiving
chemotherapy also had worse OS (16months compared
with 37 for those receiving endocrine) and this was signifi-
cant [19] but an Italian study showed the reverse (38
months OS following 1st LoT chemotherapy compared
with 33months following endocrine therapy) [27]. Differ-
ences between countries may reflect patient mix and
patterns of follow up after diagnosis of early BC.
Shorter OS for patients receiving chemotherapy as 1st
LoT most likely reflects their more aggressive underlying
disease as noted above. Indeed, presence of visceral
metastasis was highly correlated with 1st LoT chemo-
therapy in our study and associated with worse OS (23
months for patients with visceral metastasis compared
with 37months for those with non-visceral metastasis).
In a Cox regression analysis, it was the sites of
metastasis that proved to be the dominant factor
influencing OS, though we acknowledge that the total
number of observations is small and this model may
have low power.
The apparently worse outcomes seen with chemother-
apy emphasize the limitations of chemotherapy in this
patient group. Indeed, in our study 30% of patients
treated with first line chemotherapy did not subse-
quently receive an endocrine agent. Moreover, it sug-
gests that there may be significant benefits if endocrine
therapy was used more frequently and earlier for
patients with more aggressive HR+/HER2- MBC. The
efficacy and tolerability of 1st LoT SACT with endocrine
therapy and the emerging use of CDK4/6 inhibitors
suggests that the trend towards falling use of chemother-
apy observed in this setting may indeed continue.
This study has both strengths and weaknesses.
Strengths include it being a single centre study of pa-
tients treated by a single team of non-surgical oncolo-
gists. The period over which patients were treated is also
relevant when gauging the treatment landscape prior to
the introduction of CDK4/6 inhibitors. The main limita-
tion of the study is that, coming from a single centre,
the size of our patient cohort was limited; this enabled
us, however, to gather data both from the EPR directly
and by inspection. Including patients diagnosed with
MBC before 2012 would have increased patient numbers
but at the price of the cohort being less contemporary
and potentially less relevant. Including patients treated
within a clinical trial (prior to or during the study
period) would also have increased the cohort, but this
was not compatible with original study aims to describe
routine real-world clinical practice. The US real world
study was much larger, but was based on an insurance
claim database and collected limited clinical data [21].
We collected more data, but the study was not designed
to characterise aspects of treatment such as whether
endocrine treatment following chemotherapy was being
used as “maintenance” treatment or because of disease
progression.
Real-world studies complement well designed clinical
trials and allow for cost-effective analysis of large and
representative patient populations, many of whom would
be excluded from clinical trials. They provide an import-
ant perspective on clinical practice and patient outcomes
in ordinary healthcare settings. Rapid developments in
EPRs and the ability to link clinical informatics in
primary and secondary care, raise the prospect of inte-
grating databases such that information on other ex-
planatory variables such as co-morbidities and social
factors becomes available at scale. There is also the
potential to look at how real-world outcomes evolve
with the introduction of new treatments and to gauge
their wider societal impact. For example, the ongoing
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Epidemiological Strategy and Medical Economics
(ESME) research programme is centralising real-life data
on more than 16,000 patients with BC from a single
French Comprehensive Cancer Centre for research
purposes [28].
In conclusion, this study demonstrates the heteroge-
neous patterns of SACT treatment of patients with
HR+/HER2- MBC exclusive of clinical trial involvement.
Looking ahead, there is opportunity for increased use of
combination endocrine therapy as 1st LoT, delaying the
introduction of chemotherapy and perhaps limiting the
number of lines of subsequent treatment. This further
emphasizes the need to optimise use of the most effect-
ive and best tolerated SACT earlier in the natural history
of MBC. We plan to repeat this work in a future cohort
of patients treated after CDK4/6 inhibitors became
available through the NHS.
Supplementary information is available at the BMC
Cancer website.
Conclusions
In real-world clinical practice, diverse endocrine therap-
ies predominate as 1st LoT for patients with HR+/
HER2- MBC. Use of chemotherapy as 1st LoT is associ-
ated with more aggressive disease in younger patients. In
a context of personalised treatment, use of effective and
tolerable therapies to treat MBC early is important.
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